Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Eric R. Lutz

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5086599253. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
35
Papers, trials and grants by year

2013: 2 papers, 1 grant · 2014: 1 paper · 2015: 2 papers · 2016: none · 2017: none · 2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 8

  1. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and … Co-author DOI 10.1016/j.ijrobp.2024.10.039↗
  2. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.122092↗
  3. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. Co-author DOI 10.1172/jci.insight.122857↗
  4. Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patient… Co-author DOI 10.1186/2051-1426-3-s2-p155↗
  5. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Co-author DOI 10.1200/jco.2014.57.4244↗
  6. Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. Co-author DOI 10.4161/21624011.2014.962401↗
  7. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. First author DOI 10.1097/cji.0b013e31829fb7a2↗
  8. Development of mutome-specific personalized vaccines for pancreatic cancer Co-author DOI 10.1186/2051-1426-1-s1-p224↗

Grants 1

  1. Career Development Award: Eric Lutz (cancer mutome for personalized immunotherapy) AWARD pancan:2013-eric-lutz-phd-career-development-award-eric-lutz-cance

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Elizabeth M. Jaffee · 8 shared papers, 2013–2025 · strength 0.56
  2. Dung Thi Le · 5 shared papers, 2013–2025 · strength 0.39
  3. Daniel A. Laheru · 5 shared papers, 2013–2025 · strength 0.39
  4. Lei Zheng · 2 shared papers, 2013–2025 · strength 0.23
  5. Lauren M. Rosati · 1 shared paper, 2025 · strength 0.20
  6. Matthew John Weiss · 1 shared paper, 2025 · strength 0.20
  7. Amy Hacker‐Prietz · 1 shared paper, 2025 · strength 0.20
  8. Colin Hill · 1 shared paper, 2025 · strength 0.20
  9. Joseph M. Herman · 1 shared paper, 2025 · strength 0.20
  10. Christopher L. Wolfgang · 1 shared paper, 2025 · strength 0.20
  11. Timothy Michael Pawlik · 1 shared paper, 2025 · strength 0.20
  12. Amol Kumar Narang · 1 shared paper, 2025 · strength 0.20
  13. Richard David Schulick · 1 shared paper, 2025 · strength 0.20
  14. Heather L. Kinkead · 3 shared papers, 2013–2018 · strength 0.17
  15. Alexander C. Hopkins · 2 shared papers, 2018 · strength 0.15
  16. Mark M. Yarchoan · 2 shared papers, 2018 · strength 0.15
  17. Dirk G. Brockstedt · 3 shared papers, 2013–2015 · strength 0.12
  18. Todd S. Crocenzi · 2 shared papers, 2015 · strength 0.08
  19. Jennifer N. Uram · 2 shared papers, 2013–2015 · strength 0.07
  20. Annie A. Wu · 1 shared paper, 2018 · strength 0.07
  21. Neeha Zaidi · 1 shared paper, 2018 · strength 0.07
  22. Lei Zheng · 1 shared paper, 2014 · strength 0.06
  23. Andrew H. Ko · 1 shared paper, 2015 · strength 0.04
  24. Robert H. Vonderheide · 1 shared paper, 2015 · strength 0.04
  25. George Albert Fisher · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.